Crowdfunding site Indiegogo is an unconventional marketing tool for the medical device world, but for NeuroMetrix it appears to have paid off.
MassDevice.com asks medical device CEOs about the key issues of 2014 and what's ahead for the New Year.
As 2014 draws to a close, MassDevice.com asked several medical device company CEOs for their takes on 2014 and what they're looking for in 2015.
We wanted to get their views on the major trends seen in medtech this year, including the red-hot M&A and IPO scenes, the medical device tax, the regulatory environment in the U.S., and more.
NeuroMetrix taps a Philips Oral Healthcare and Johnson & Johnson veteran to develop a consumer business for its over-the-counter pain management system.
NeuroMetrix says the FDA granted 510(k) clearance for over-the-counter sales of its wearable chronic pain device.
Jorge Quinoy, president of Volcano Corp.'s U.S. & APLAC commercial sales, is leaving the company effective today.
Volcano (NSDQ:VOLC) said last week that its president for U.S. & APLAC commercial sales, Jorge (George) Quinoy, is leaving the company effective today.
Omron healthcare will distribute in Japan.
NeuroMetrix's shares jump nearly 20% after the company lands Japanese marketing approval for its NC-stat DPNCheck for detecting diabetic peripheral neuropathy.
NeuroMetrix (NSDQ:NURO) got a major Wall Street boost today after announcing Japanese market approval for its NC-stat DPNCheck test for diabetic peripheral neuropathy.